JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Bond ETF
BNDX
|
+$2.3B |
| 2 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$1.64B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.55B |
| 4 |
iShares MBS ETF
MBB
|
+$1.29B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.14B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$693M |
| 2 |
CVS Health
CVS
|
+$676M |
| 3 |
Johnson & Johnson
JNJ
|
+$669M |
| 4 |
Mondelez International
MDLZ
|
+$593M |
| 5 |
UnitedHealth
UNH
|
+$572M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.25% |
| 2 | Technology | 12.49% |
| 3 | Financials | 12.17% |
| 4 | Healthcare | 9.9% |
| 5 | Consumer Discretionary | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IMDX
4476
Insight Molecular Diagnostics
IMDX
$120M
| $181K | ﹤0.01% |
2,289
+2,274
| +15,160% | +$147K |
2017 Q4
5 quarters
|
|
|
ACGN
4477
DELISTED
Aceragen Inc
ACGN
| $181K | ﹤0.01% |
4,173
+659
| +19% | +$31.9K |
2015 Q1
16 quarters
|
|
4478
Banc of California
BANC
$2.78B
| $179K | ﹤0.01% |
12,934
-493
| -4% | -$7.36K |
2017 Q2
7 quarters
|
|
4479
Fortuna Silver Mines
FSM
$3.3B
| $179K | ﹤0.01% |
53,471
-449,131
| -89% | -$1.66M |
2018 Q3
2 quarters
|
|
|
AFT
4480
DELISTED
Apollo Senior Floating Rate Fund Inc.
AFT
| $179K | ﹤0.01% |
12,090
-26
| -0.2% | -$384 |
2015 Q3
14 quarters
|
|
4481
iShares Core 10+ Year USD Bond ETF
ILTB
$579M
| $178K | ﹤0.01% |
2,842
-130
| -4% | -$7.84K |
2014 Q3
18 quarters
|
|
4482
Vanguard World Funds Extended Duration ETF
EDV
$3.37B
| $177K | ﹤0.01% |
1,489
+814
| +121% | +$92.5K |
2018 Q4
1 quarter
|
|
4483
Natera
NTRA
$61.4B
| $177K | ﹤0.01% |
8,587
-154,168
| -95% | -$2.42M |
2017 Q4
5 quarters
|
|
4484
ProQR Therapeutics
PRQR
$236M
| $177K | ﹤0.01% |
+12,775
| New | +$191K |
2019 Q1
0 quarters
|
|
|
CARO
4485
DELISTED
Carolina Financial Corp.
CARO
| $177K | ﹤0.01% |
5,128
-240
| -4% | -$8.32K |
2017 Q4
5 quarters
|
|
|
FLY
4486
DELISTED
Fly Leasing Limited
FLY
| $177K | ﹤0.01% |
12,788
+9,158
| +252% | +$108K |
2018 Q2
3 quarters
|
|
4487
First Mid Bancshares
FMBH
$1.32B
| $176K | ﹤0.01% |
5,293
-6,705
| -56% | -$227K |
2017 Q4
5 quarters
|
|
4488
State Street Global Allocation ETF
GAL
$318M
| $176K | ﹤0.01% |
4,673
| – | – |
2015 Q1
16 quarters
|
|
4489
Amphastar Pharmaceuticals
AMPH
$1.08B
| $175K | ﹤0.01% |
8,542
-125,296
| -94% | -$2.81M |
2014 Q3
18 quarters
|
|
|
COOP
4490
DELISTED
Mr. Cooper
COOP
| $174K | ﹤0.01% |
18,154
-853
| -4% | -$11.5K |
2015 Q4
13 quarters
|
|
|
EVM
4491
DELISTED
Eaton Vance California Municipal Bond Fund
EVM
| $174K | ﹤0.01% |
+16,499
| New | +$172K |
2019 Q1
0 quarters
|
|
4492
Nutanix
NTNX
$19.9B
| $174K | ﹤0.01% |
4,625
-2,875,464
| -100% | -$132M |
2016 Q3
10 quarters
|
|
|
MEET
4493
DELISTED
The Meet Group, Inc. Common Stock
MEET
| $174K | ﹤0.01% |
34,571
-206,072
| -86% | -$1.15M |
2017 Q1
8 quarters
|
|
|
BANX
4494
ArrowMark Financial
BANX
$195M
| $173K | ﹤0.01% |
8,045
-10,300
| -56% | -$213K |
2017 Q1
8 quarters
|
|
4495
Daktronics
DAKT
$856M
| $173K | ﹤0.01% |
23,166
+83
| +0.4% | +$643 |
2016 Q3
10 quarters
|
|
4496
CALL
Rigel Pharmaceuticals
RIGL
$893M
| $173K | ﹤0.01% |
6,750
-3,250
| -33% | -$74.3K |
2018 Q3
2 quarters
|
|
|
4497
PUT
Rigel Pharmaceuticals
RIGL
$893M
| $173K | ﹤0.01% |
6,750
-3,250
| -33% | -$74.3K |
2018 Q3
2 quarters
|
|
4498
Veracyte
VCYT
$3.83B
| $173K | ﹤0.01% |
6,903
-69,749
| -91% | -$1.33M |
2017 Q3
6 quarters
|
|
|
PAMT
4499
PAMT Corp
PAMT
$252M
| $173K | ﹤0.01% |
14,104
+3,604
| +34% | +$44.5K |
2016 Q4
9 quarters
|
|
|
APLS
4500
DELISTED
Apellis Pharmaceuticals
APLS
| $172K | ﹤0.01% |
8,811
-414
| -4% | -$6.51K |
2017 Q4
5 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2019 Portfolio in Review
As of Q1 2019, JP Morgan Chase held 6,314 positions worth $490B, up 13% from $432B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q1 2019 filing shows 537 new, 2,080 increased, 2,670 reduced and 537 closed positions. Its largest new stake was Lyft: 2,510,596 shares worth $197M. The largest sale was Apple, an estimated $693M.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 26% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q1 2019 buy was Lyft: 2,510,596 shares worth $197M.
- JP Morgan Chase added most to Vanguard Total International Bond ETF in Q1 2019, an estimated $2.3B increase.
- JP Morgan Chase's biggest Q1 2019 reduction was Apple, cutting an estimated $693M.
- JP Morgan Chase fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $164M.
- JP Morgan Chase's ten largest holdings make up 16% of its $490B portfolio in Q1 2019.
- JP Morgan Chase opened 537 new positions and closed 537 in Q1 2019.
- JP Morgan Chase's portfolio value rose 13% quarter-over-quarter to $490B.
Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.